You can adjust the available sliders to ‘Enabled’ or ‘Disabled’, then click ‘Save and Accept’. The MHRA has issued an alert to healthcare professionals regarding the recall of these prescription medications. February 27, 2020 -- American Health Packaging has voluntarily recalled eleven (11) lots of Ranitidine Tablets, USP 150 mg, 100 count Unit Dose Blisters to the consumer level due to the potential N-Nitrosodimethylamine (NDMA) amounts above levels established by the FDA.

View our Necessary cookies are absolutely essential for the website to function properly. It will take only 2 minutes to fill in. By clicking "I agree" you consent to the use of cookies for non-essential functions and the related processing of personal data. The UK Medicines and Healthcare products Regulatory Agency (MHRA) has issued alerts to healthcare professionals and retailers that Perrigo Company is precautionarily recalling its ranitidine medicines. Other Ranitidine products have been quarantined, and the Department of Health and Social Care (DHSC) issued an Dr Andrew Gray, MHRA Deputy Director of Inspections, Enforcement & Standards, comments:“Whilst this action is precautionary, the MHRA takes patient safety very seriously.“Patients should keep taking their current medicines but should speak to their doctor or pharmacist if they are concerned and should seek their doctor’s advice before stopping any prescribed medicines.“We have asked companies to quarantine batches of potentially affected medicines whilst we investigate and we will take action as necessary, including product recalls where appropriate.“We have also requested risk assessments from the relevant companies which will include the testing of potentially affected batches.“Currently, there is no evidence that medicines containing nitrosamines have caused any harm to patients, but the Agency is closely monitoring the situation, and working with other Regulatory Agencies around the world.”MHRA is a centre of the Medicines and Healthcare products Regulatory Agency which also includes the Don’t include personal or financial information like your National Insurance number or credit card details.To help us improve GOV.UK, we’d like to know more about your visit today. All remaining stock should be quarantined and returned without delay to the supplier.Patients should not stop taking their medication, and a treatment review is not necessary until the next routine appointment.The recall is a precautionary measure due to possible contamination of the active substance in Zantac, ranitidine, with an impurity called NDMA (N-nitrosodimethylamine) which has been identified as a risk factor in the development of certain cancers.The MHRA is actively involved with the European Medicines Agency (EMA) and other medicines regulators to determine the impact of what is an ongoing, global issue. But opting out of some of these cookies may have an effect on your browsing experience. In September 2019, the carcinogen N -nitrosodimethylamine (NDMA) was discovered in ranitidine products from a number of manufacturers, resulting in recalls. The Medicines and Healthcare products Regulatory Agency (MHRA) on Monday issued a class two medicines recall for all unexpired stocks of ranitidine 150 mg and 300 mg tablets by Medreich Plc. MHRA (Medicines) Drug Alerts - Non-NHS Recipients; GP - Locum; GP Practices; Action category: Action: Title: Ranitidine: all oral formulations.

OTC Concepts Ltd, Relconchem Ltd, Noumed Life Sciences and Medreich PLC recall The MHRA has issued an alert to healthcare professionals, as Teva UK Ltd is recalling all unexpired stock of certain batches of 2 types of Ranitidine medicines used to treat conditions such as heartburn and stomach ulcers.The 2 products affected are Ranitidine Effervescent Tablets 150 micrograms and 300 mg. Out of these cookies, the cookies that are categorised as ”Necessary” are stored on your browser as they are as essential for the working of basic functionalities of the website. These cookies will be stored in your browser only with your consent. “We have also requested risk assessments from the relevant companies which will include the testing of potentially affected batches.…retailers have been advised to stop supplying the recalled products immediately and for all remaining stock to be quarantined and returned”“Currently, there is no evidence that medicines containing nitrosamines have caused any harm to patients, but the Agency is closely monitoring the situation and working with other Regulatory Agencies around the world.”The MHRA has said it is actively involved with the European Medicines Agency (EMA) and other medicines’ regulators to determine the impact of what is an ongoing, global issue.All subscriptions include online membership, giving you access to the journal and exclusive content.This website uses cookies to improve your experience while you navigate through the website.
The Medicines and Healthcare products Regulatory Agency (MHRA) today issued a class two medicines recall for all unexpired stocks of ranitidine 150 mg and 300 mg film-coated tablets by Accord Healthcare. The UK healthcare agency has issued an alert for Perrigo ranitidine products, recalling and quarantining certain batches.The possible contamination of ranitidine with probable human carcinogen N-nitrosodimethylamine (NDMA) has promoted the recall.All unexpired stock of certain batches of the ranitidine 150mg/10ml oral solution produced by the company are being recalled. On 8 October, a drug alert was also issued regarding the An investigation into other potentially impacted products is continuing and further updates will be provided as the investigation progresses. These cookies do not store any personal information.Analytics cookies collect information about your use of the content, and in combination with previously collected information, are used to measure, understand, and report on your usage of this website.Advertising and targeting cookies help us provide our visitors with relevant ads and marketing campaigns.This website uses cookies to enable, optimise and analyse site operations, as well as to provide personalised content and allow you to connect to social media. The Department of Health and Social Care (DHSC) issued a Medicine Supply Notification MSN/2020/025 last week updating healthcare professionals on all formulations of ranitidine following the ongoing regulatory investigations on the presence of N-nitrosodimethylamine (NDMA) contaminant: All pharmacies should have received this in the NHSmail inbox